These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 4074426

  • 1. Effect of cilostazol on platelet aggregation and experimental thrombosis.
    Kimura Y, Tani T, Kanbe T, Watanabe K.
    Arzneimittelforschung; 1985; 35(7A):1144-9. PubMed ID: 4074426
    [Abstract] [Full Text] [Related]

  • 2. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease.
    Yasunaga K, Mase K.
    Arzneimittelforschung; 1985; 35(7A):1186-8. PubMed ID: 4074431
    [Abstract] [Full Text] [Related]

  • 3. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
    Yasunaga K, Mase K.
    Arzneimittelforschung; 1985; 35(7A):1189-92. PubMed ID: 4074432
    [Abstract] [Full Text] [Related]

  • 4. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S, Toba Y, Suzuki S, Ninomiya S, Umezato M, Hiyama T.
    Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study.
    Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y.
    Arzneimittelforschung; 1987 May; 37(5):563-6. PubMed ID: 2956957
    [Abstract] [Full Text] [Related]

  • 6. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.
    Shintani S, Watanabe K, Kawamura K, Mori T, Tani T, Toba Y, Sasabe H, Nakagiri N, Hongoh O, Fujita S.
    Arzneimittelforschung; 1985 May; 35(7A):1163-72. PubMed ID: 3000392
    [Abstract] [Full Text] [Related]

  • 7. Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
    Kawamura K, Fujita S, Tani T, Kimura Y.
    Arzneimittelforschung; 1985 May; 35(7A):1154-6. PubMed ID: 4074428
    [Abstract] [Full Text] [Related]

  • 8. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation.
    Kawamura K, Watanabe K, Kimura Y.
    Arzneimittelforschung; 1985 May; 35(7A):1149-54. PubMed ID: 4074427
    [Abstract] [Full Text] [Related]

  • 9. Effect of vintoperol on platelet aggregation and experimental thrombosis.
    Csomor K, Kárpáti E.
    Arzneimittelforschung; 1994 Jan; 44(1):36-40. PubMed ID: 8135876
    [Abstract] [Full Text] [Related]

  • 10. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals.
    Momo K, Someya K, Tachiiri T, Mitsuoka Y, Nakamura K, Imai S, Ino T, Ohkubo H.
    Arzneimittelforschung; 1992 Jan; 42(1):32-9. PubMed ID: 1586377
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.
    Kim CW, Yun JW, Bae IH, Park YH, Jeong YS, Park JW, Chung JH, Park YH, Lim KM.
    Thromb Res; 2011 Jun; 127(6):565-70. PubMed ID: 21420150
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities.
    Kamiya T, Sakaguchi S.
    Arzneimittelforschung; 1985 Jun; 35(7A):1201-3. PubMed ID: 4074435
    [Abstract] [Full Text] [Related]

  • 13. Effects of cilostazol on platelet function.
    Uehara S, Hirayama A.
    Arzneimittelforschung; 1989 Dec; 39(12):1531-4. PubMed ID: 2487508
    [Abstract] [Full Text] [Related]

  • 14. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.
    Akiyama H, Kudo S, Shimizu T.
    Arzneimittelforschung; 1985 Dec; 35(7A):1133-40. PubMed ID: 4074424
    [Abstract] [Full Text] [Related]

  • 15. Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction.
    Kobayashi S, Yamaguchi S, Katsube T, Kitani M, Okada K, Tsunematsu T.
    Arzneimittelforschung; 1985 Dec; 35(7A):1193-7. PubMed ID: 4074433
    [Abstract] [Full Text] [Related]

  • 16. The localization of a new antithrombotic agent, cilostazol, in CHO-K1 cells as demonstrated by autoradiography.
    Usuda N, Nagata T, Naka M, Hidaka H.
    Arzneimittelforschung; 1985 Dec; 35(7A):1141-3. PubMed ID: 4074425
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans.
    Yasuda K, Sakuma M, Tanabe T.
    Arzneimittelforschung; 1985 Dec; 35(7A):1198-200. PubMed ID: 4074434
    [Abstract] [Full Text] [Related]

  • 18. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors, IV. Synthesis and biological activity of the metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl)butoxy]-2-oxo-1,2,3,4- tetrahydroquinoline (OPC-13013).
    Nishi T, Tabusa F, Tanaka T, Shimizu T, Nakagawa K.
    Chem Pharm Bull (Tokyo); 1985 Mar; 33(3):1140-7. PubMed ID: 4028296
    [No Abstract] [Full Text] [Related]

  • 19. Effect of cilostazol on experimental cerebral infarction in rabbits.
    Watanabe K, Nakase H, Kimura Y.
    Arzneimittelforschung; 1986 Jul; 36(7):1022-4. PubMed ID: 3094546
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation.
    Jin YR, Ryu CK, Moon CK, Cho MR, Yun YP.
    Pharmacology; 2004 Apr; 70(4):195-200. PubMed ID: 15001820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.